Abstract
Pancreatic cancer is characterized by its intrinsic resistance to cytotoxic agents. But the underlying molecular mechanism is unclear. Studies demonstrate that angiogenesis, presence of highly resistant cancer stem cells (CSCs), dysregulation of cell cycle and apoptosis are main aspects of mechanisms of pancreatic cancer chemoresistance. Interestingly, recent investigations of Wnt/β-catenin signaling suggest roles for the signaling in these four aspects and the pathogenesis of pancreatic cancer. Conceivably, the dysregulation of Wnt/β-catenin signaling pathway is involved in pancreatic cancer chemoresistance. Though researchers have proven it in some other cancer types, however, there is no direct evidence for this reasoning in pancreatic cancer. Designing effective experiment setups to define the function and mechanism of Wnt/β-catenin signaling in pancreatic cancer chemoresistance and subsequently targeting the signaling to improve the sensitivity of chemotherapy in pancreatic cancer require a full understanding of the molecular mechanisms of Wnt/β-catenin signaling pathway in angiogenesis, maintaining of highly resistant CSCs, regulation of cell cycle and apoptosis in pancreatic cancer.
Keywords: Wnt/β-catenin signaling, angiogenesis, chemoresistance, pancreatic cancer
Current Pharmaceutical Design
Title:Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Volume: 18 Issue: 17
Author(s): Jiujie Cui, Weihua Jiang, Shuyi Wang, Liwei Wang and Keping Xie
Affiliation:
Keywords: Wnt/β-catenin signaling, angiogenesis, chemoresistance, pancreatic cancer
Abstract: Pancreatic cancer is characterized by its intrinsic resistance to cytotoxic agents. But the underlying molecular mechanism is unclear. Studies demonstrate that angiogenesis, presence of highly resistant cancer stem cells (CSCs), dysregulation of cell cycle and apoptosis are main aspects of mechanisms of pancreatic cancer chemoresistance. Interestingly, recent investigations of Wnt/β-catenin signaling suggest roles for the signaling in these four aspects and the pathogenesis of pancreatic cancer. Conceivably, the dysregulation of Wnt/β-catenin signaling pathway is involved in pancreatic cancer chemoresistance. Though researchers have proven it in some other cancer types, however, there is no direct evidence for this reasoning in pancreatic cancer. Designing effective experiment setups to define the function and mechanism of Wnt/β-catenin signaling in pancreatic cancer chemoresistance and subsequently targeting the signaling to improve the sensitivity of chemotherapy in pancreatic cancer require a full understanding of the molecular mechanisms of Wnt/β-catenin signaling pathway in angiogenesis, maintaining of highly resistant CSCs, regulation of cell cycle and apoptosis in pancreatic cancer.
Export Options
About this article
Cite this article as:
Cui Jiujie, Jiang Weihua, Wang Shuyi, Wang Liwei and Xie Keping, Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092464
DOI https://dx.doi.org/10.2174/13816128112092464 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
Current Cancer Drug Targets Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Involvement of Adipogenic Potential of Human Bone Marrow Mesenchymal Stem Cells (MSCs) in Osteoporosis
Current Stem Cell Research & Therapy